185 related articles for article (PubMed ID: 33688197)
1. Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma.
Jezeršek Novaković B; Boltežar L; Novaković A
Ther Clin Risk Manag; 2021; 17():183-192. PubMed ID: 33688197
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
[TBL] [Abstract][Full Text] [Related]
3. Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Volpetti S; Zaja F; Fanin R
Onco Targets Ther; 2014; 7():865-72. PubMed ID: 24926199
[TBL] [Abstract][Full Text] [Related]
4. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
5. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
Zinzani PL; Corradini P; Martelli M; Minotti G; Oliva S; Spina M; Barosi G; Tura S
Eur J Haematol; 2016 Dec; 97(6):554-561. PubMed ID: 27124765
[TBL] [Abstract][Full Text] [Related]
6. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.
Boyle EM; Morschhauser F
Expert Opin Drug Saf; 2015 Apr; 14(4):601-7. PubMed ID: 25716061
[TBL] [Abstract][Full Text] [Related]
7. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Pettengell R; Sebban C; Zinzani PL; Derigs HG; Kravchenko S; Singer JW; Theocharous P; Wang L; Pavlyuk M; Makhloufi KM; Coiffier B
Br J Haematol; 2016 Sep; 174(5):692-9. PubMed ID: 27118109
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Pettengell R; Coiffier B; Egorov A; Singer J; Sivcheva L
Clin Drug Investig; 2018 Jun; 38(6):527-533. PubMed ID: 29564722
[TBL] [Abstract][Full Text] [Related]
9. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
Mukherji D; Pettengell R
Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Hübel K
Expert Opin Pharmacother; 2018 Nov; 19(16):1829-1834. PubMed ID: 30269614
[TBL] [Abstract][Full Text] [Related]
11. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
[TBL] [Abstract][Full Text] [Related]
12. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
[TBL] [Abstract][Full Text] [Related]
13. Pixantrone maleate for non-Hodgkin's lymphoma.
Mukherji D; Pettengell R
Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Jamal-Hanjani M; Pettengell R
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1441-8. PubMed ID: 21905966
[TBL] [Abstract][Full Text] [Related]
15. Pixantrone: novel mode of action and clinical readouts.
Minotti G; Han H; Cattan V; Egorov A; Bertoni F
Expert Rev Hematol; 2018 Jul; 11(7):587-596. PubMed ID: 29912583
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Heyman B; Rizzieri D; Adams DJ; De Castro C; Diehl L; Li Z; Moore J; Beaven A
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):679-686. PubMed ID: 30166257
[TBL] [Abstract][Full Text] [Related]
17. Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma.
Novakovic A; Boltezar L; Novakovic BJ
Oncol Lett; 2020 Mar; 19(3):2028-2034. PubMed ID: 32194699
[TBL] [Abstract][Full Text] [Related]
18. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
Péan E; Flores B; Hudson I; Sjöberg J; Dunder K; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2013; 18(5):625-33. PubMed ID: 23615696
[TBL] [Abstract][Full Text] [Related]
19. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
El-Helw LM; Hancock BW
Expert Opin Investig Drugs; 2007 Oct; 16(10):1683-91. PubMed ID: 17922631
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]